TY - JOUR
T1 - An intermittent approach for cancer chemoprevention
AU - Wu, Xiangwei
AU - Lippman, Scott M.
N1 - Funding Information:
This work is supported in part by a CPRIT grant RP110107 to X.W. and the institutional core/CCSG grant 5P30 CA-16672-36 from US NIH/NCI.
PY - 2011/12
Y1 - 2011/12
N2 - Cancer chemoprevention approaches generally use long-term, continuous treatment, which can produce major preventive effects but which can also have unexpected serious adverse events. This raises the question of whether intermittent dosing schedules might reduce toxicity while retaining benefit, a concept that we call short-term intermittent therapy to eliminate premalignancy (SITEP). Recent preclinical studies support a novel SITEP approach whereby short-term, intermittent therapy eliminates premalignant cells via apoptosis that is induced by synthetic lethal interactions. Synthetic lethality allows personalized, selective elimination of premalignant clones without harming normal cells. This Opinion article provides a detailed discussion of the principle, method and future development of the SITEP approach.
AB - Cancer chemoprevention approaches generally use long-term, continuous treatment, which can produce major preventive effects but which can also have unexpected serious adverse events. This raises the question of whether intermittent dosing schedules might reduce toxicity while retaining benefit, a concept that we call short-term intermittent therapy to eliminate premalignancy (SITEP). Recent preclinical studies support a novel SITEP approach whereby short-term, intermittent therapy eliminates premalignant cells via apoptosis that is induced by synthetic lethal interactions. Synthetic lethality allows personalized, selective elimination of premalignant clones without harming normal cells. This Opinion article provides a detailed discussion of the principle, method and future development of the SITEP approach.
UR - http://www.scopus.com/inward/record.url?scp=81855207248&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81855207248&partnerID=8YFLogxK
U2 - 10.1038/nrc3167
DO - 10.1038/nrc3167
M3 - Review article
C2 - 22071977
AN - SCOPUS:81855207248
SN - 1474-175X
VL - 11
SP - 879
EP - 885
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
IS - 12
ER -